ClinicalTrials.gg
Active, not recruitingNCT05371613COMPASSUpdated Sep 9, 2026

A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)

A Phase 2/3 interventional study of tividenofusp alfa and idursulfase in Mucopolysaccharidosis II, sponsored by Denali Therapeutics Inc.. Active, not recruiting at 30 sites in 14 countries. Open to participants aged 2 Years to 25 Years. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by Denali Therapeutics Inc. · Phase 2/3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
2 Years to 25 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies testing idursulfase in Mucopolysaccharidosis II — none open to participants now, 2 under way, 2 of them phase 3. idursulfase · Mucopolysaccharidosis II.

Enrollment
3rd of 12
65 · median 30
Started
2022
with 1 other
Phase 2/3
6 of 12
none open now
Registered
10th of 12
by date
Lead sponsor
1 of 12
Denali Therapeutics Inc.

Among the 12 studies testing idursulfase in Mucopolysaccharidosis II, this one is the 3rd largest by enrollment, is one of 2 that started in 2022, is one of 6 in phase 2/3, and was the 10th registered.

Mucopolysaccharidosis II

77 studies on the registry are indexed under Mucopolysaccharidosis II; 8 are open to participants now.

Browse Mucopolysaccharidosis II studies →

Open to participants now

None of the 12 studies testing idursulfase in Mucopolysaccharidosis II is open now. The open studies under Mucopolysaccharidosis II, anywhere →

About idursulfase

idursulfase: first FDA approval 2006 (ELAPRASE), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 4 Mucopolysaccharidosis II studies recruiting now, 1 sets no upper age limit and 3 stop at 75 or younger; 4 take children under 18; none take healthy volunteers.

This study: 2 Years to 25 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing idursulfase in Mucopolysaccharidosis II as a file.
02

Study summary

This is a Phase 2/3, multiregional, two-arm, double-blind, randomized, active (standard-of-care)-controlled study of the efficacy and safety of tividenofusp alfa (DNL310), an investigational central nervous system (CNS)-penetrant enzyme-replacement therapy (ERT) for mucopolysaccharidosis type II (MPS II).

Participants may also qualify to enter an open-label treatment phase with DNL310 or idursulfase based on pre-specified criteria.

03

Conditions studied

  • Mucopolysaccharidosis II

Keywords

  • Hunter Syndrome
  • MPS II
  • nMPS II
  • nnMPS II
04

Who can participate

Ages eligible
2 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participants aged ≥2 to \<6 years (Cohort A) or ≥6 to \<26 years (Cohort B)
  • Confirmed diagnosis of MPS II (for Cohort A, nMPS II; for Cohort B, nnMPS II)
  • Have no history of treatment with enzyme replacement therapy (ERT) OR not have received continuous ERT for 4 months prior to screening OR be on maintenance ERT and have tolerated idursulfase for a minimum of 4 months prior to screening

Key Exclusion Criteria:

  • Have a documented mutation of other genes or genetic diagnosis accounting for developmental delay
  • Previously received an iduronate 2-sulfatase (IDS) gene therapy or stem cell therapy
  • Received any CNS-targeted MPS ERT within 6 months prior to screening
  • Have a for lumbar punctures and/or magnetic resonance imaging (MRI)
  • Participated in any other drug study or used an investigational drug within 60 days prior to screening or intend to receive another investigational drug during the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
65 participants (actual)

Study arms

  • Experimental
    Cohort A: Participants with nMPS II

    Drug: tividenofusp alfa · Drug: idursulfase

  • Experimental
    Cohort B: Participants with nnMPS II

    Drug: tividenofusp alfa · Drug: idursulfase

  • Experimental
    Open-label Treatment Phase

    Participants who meet pre-specified criteria may receive DNL310 or idursulfase

    Drug: tividenofusp alfa · Drug: idursulfase

Interventions

06

What researchers measure

Primary outcomes

  1. Ratio to baseline in cerebrospinal fluid (CSF) heparan sulfate (HS) concentration (Cohort A)

    Time frame: 24 weeks

  2. Change from baseline in the Vineland Adaptive Behavior Scale, Third Edition (Vineland-3)(Cohort A)

    Time frame: 96 weeks

Secondary outcomes

  1. Change from baseline in the Bayley Scales of Infant and Toddler Development, Third Edition (BSID-III)(Cohort A only)

    Time frame: 96 weeks

  2. Change from baseline in the Vineland-3 Adaptive Behavior Composite (ABC) score (Cohort A only)

    Time frame: 96 weeks

  3. Ratio to baseline in serum neurofilament light chain (NfL) (Cohort A only)

    Time frame: 96 weeks

  4. Change from baseline in distance walked in the Six-Minute Walk Test (6MWT; Cohort B only)

    Time frame: 48 weeks

  5. Ratio to baseline in the sum of urine HS and dermatan sulfate (DS) concentrations (normalized to creatinine) (Cohorts A and B)

    Time frame: up to 48 weeks

  6. Liver volume within the normal range (normal vs abnormal) as measured by magnetic resonance imaging (MRI) (Cohorts A and B)

    Time frame: 48 weeks

  7. Spleen volume within the normal range (normal vs abnormal) as measured by MRI (Cohorts A and B)

    Time frame: 48 weeks

  8. Improvement in Parent/Caregiver Global Impression of Change (CaGI-C) Overall MPS II (Cohorts A and B)

    Time frame: 48 weeks

07

Study locations

30 sites
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2022 (actual). Primary completion is estimated for Dec 2027, 65 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2022
First posted
May 12, 2022
StartActual
Jul 21, 2022
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05371613
Lead sponsor
Denali Therapeutics Inc.
Responsible party
Sponsor
First posted
May 12, 2022
Start date
Jul 21, 2022
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Sep 9, 2026

Study contacts

Jose Alcantara Rodriguez, PharmD
study director · Denali Therapeutics Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tividenofusp alfa · Idursulfase

Start the discussion